Tetrathiomolybdate

Identification

Name
Tetrathiomolybdate
Accession Number
DB05088
Description

Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 224.19
Monoisotopic: 225.794787
Chemical Formula
MoS4
Synonyms
  • Thiomolybdate
  • Tiomolibdate ion
External IDs
  • ATN-224

Pharmacology

Indication

Investigated for use/treatment in liver disease and pulmonary fibrosis.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Tetrathiomolybdate demonstrated the ability to reduce toxic free copper levels and substantially improve clinical neurologic outcomes in Wilson’s patients. Studies also showed it is capable of specifically inhibiting chronic fibrotic disease processes in the lung.

Mechanism of action

Tetrathiomolybdate has demonstrated the ability to inhibit fibrosis in a number of well established animal models through the sequestration of available copper and inhibition of key fibrotric cytokines, including secreted protein acid rich in cysteine (SPARC), NFkappaB, TGF-beta, FGF-2, IL-1, IL-6, IL-8, and connective tissue growth factor (CTGF).

TargetActionsOrganism
UAmyloid beta A4 proteinNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tetrathiomolybdate.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tetrathiomolybdate.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tetrathiomolybdate.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Tetrathiomolybdate.
Technetium Tc-99m oxidronateTetrathiomolybdate may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
International/Other Brands
Copexa / Coprexa

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
91U3TGV99T
CAS number
16330-92-0
InChI Key
CXVCSRUYMINUSF-UHFFFAOYSA-N
InChI
InChI=1S/Mo.4S/q;;;2*-1
IUPAC Name
(sulfanidyldisulfanylidenemolybdenio)sulfanide
SMILES
[S-][Mo]([S-])(=S)=S

References

General References
Not Available
PubChem Compound
25199766
PubChem Substance
175426941
ChemSpider
10619308
ChEBI
30703
PDBe Ligand
4SM
Wikipedia
Tetrathiomolybdate
PDB Entries
3k7r

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentPrimary Biliary Cholangitis1
3CompletedTreatmentWilson's Disease1
2Active Not RecruitingTreatmentBreast Cancer1
2CompletedTreatmentCarcinoma, Colorectal1
2CompletedTreatmentEsophageal Carcinoma1
2CompletedTreatmentHepatocellular Carcinoma1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentPsoriasis1
2Not Yet RecruitingTreatmentWilson's Disease1
2TerminatedTreatmentBreast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)300 °C with decompositionNot Available
Predicted Properties
PropertyValueSource
logP1.57ChemAxon
pKa (Strongest Acidic)9.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity37.74 m3·mol-1ChemAxon
Polarizability14.29 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8526
Blood Brain Barrier+0.9565
Caco-2 permeable+0.5325
P-glycoprotein substrateNon-substrate0.8815
P-glycoprotein inhibitor INon-inhibitor0.9718
P-glycoprotein inhibitor IINon-inhibitor0.9958
Renal organic cation transporterNon-inhibitor0.9404
CYP450 2C9 substrateNon-substrate0.8471
CYP450 2D6 substrateNon-substrate0.8348
CYP450 3A4 substrateNon-substrate0.7961
CYP450 1A2 substrateNon-inhibitor0.7649
CYP450 2C9 inhibitorNon-inhibitor0.7287
CYP450 2D6 inhibitorNon-inhibitor0.9226
CYP450 2C19 inhibitorNon-inhibitor0.8342
CYP450 3A4 inhibitorNon-inhibitor0.9357
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7635
Ames testNon AMES toxic0.7926
CarcinogenicityCarcinogens 0.6589
BiodegradationNot ready biodegradable0.9497
Rat acute toxicity2.4587 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9173
hERG inhibition (predictor II)Non-inhibitor0.9494
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transition metal ion binding
Specific Function
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and tra...
Gene Name
APP
Uniprot ID
P05067
Uniprot Name
Amyloid beta A4 protein
Molecular Weight
86942.715 Da
References
  1. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT: The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann N Y Acad Sci. 2004 Dec;1035:34-48. [PubMed:15681799]

Drug created on October 21, 2007 16:23 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates